[Treatment and metaphylaxis of gout complicated by nephropathy and urolithiasis].
The evaluation of clinical efficacy of combined treatment and metaphylaxis in 58 patients with gout complicated by nephropathy and urolithiasis was performed. The study included 41 (71%) men and 27 (29%) women aged 44 to 88 years (mean age - 58 +/- 7 years). All patients received parenteral therapy with trometamol H, 5 -10 infusion for the course, an average of 7 infusions. For the metaphylaxis, all patients received biologically active supplement urisan 2 tablets 2 times a day during next three months against the background of drug therapy. Findings indicate a high clinical efficacy of the trometamol H in the combined treatment of patients with gout, complicated by nephropathy and urolithiasis, considering that improvement of renal function, microcirculation in the renal parenchyma, increased glomerular filtration rate, normalization of nitrogenous wastes levels, partial or complete dissolution of concretions of the kidneys, a significant decrease in the tophs size, an increase in motor activity were observed, which ultimately improves the quality of life for these patients. Metaphylaxis using urisan for 3 months on a background of traditional therapy contributed to a stable normalization of blood uric acid levels, which prevented the exacerbation of underlying disease and recurrent stone formation. These data allow to recommend reducing the dose of traditional anti-gout drugs and conducting repeated course of metaphylaxis with the urisan after 5-6 months during 3 months.
V P
VP
Avdoshin
M I
MI
Andriukhin
A V
AV
Annenkov
M N
MN
Israfilov
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000892:Anti-Infective Agents, Urinary / Q000008:administration & dosage*; D005079:Excipients / Q000008:administration & dosage*; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006073:Gout / Q000097:blood / Q000150:complications / Q000503:physiopathology / Q000517:prevention & control; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D010876:Pipemidic Acid / Q000008:administration & dosage*; D013997:Time Factors; D014325:Tromethamine / Q000008:administration & dosage*; D014527:Uric Acid / Q000097:blood; D052878:Urolithiasis / Q000097:blood / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control
D000892:Anti-Infective Agents, Urinary; D005079:Excipients; D014325:Tromethamine; D014527:Uric Acid; D010876:Pipemidic Acid